One-hour paclitaxel infusions: Review of safety and efficacy

Cancer Journal from Scientific American

Volumn 5, Issue 3, 1999, Pages 179-191

  Greco, F Anthony ^a,b   Thomas, Melodie ^a   Hainsworth, John D ^a  

^a Sarah Cannon Minnie Pearl Cancer C   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

1 hour infusions; Paclitaxel; Short infusion

Indexed keywords

PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEUKOPENIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG HYPERSENSITIVITY; ETHANOL; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; NEOPLASMS; PACLITAXEL; TIME FACTORS;

EID: 0033015901     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995;13:1609-1614.
2. Hainsworth JD, Urba WJ, Hon JK et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter, phase II trial. Eur J Cancer 1998;34: 654-658.
3. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-1870.
4. Langer CJ, Millenson M, O'Dwyer P et al. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network. Semin Oncol 1996;23[suppl 16]:35-41.
5. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1876.
6. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
7. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacokinetic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-192.
8. Klaassen U, Wilke H, Strumberg D et al. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996;2A:547-549.
9. Seidman AD. Paclitaxel via weekly 1-h infusion: dose-density with enhanced therapeutic index. Semin Oncol 1998;12[suppl 1]:19-22.
10. Chang A, Hui L, Boros R et al. Phase I study of weekly one-hour paclitaxel treatment in advanced malignant disease [abstract]. Proc Am Soc Clin Oncol 1997;16:232a.
11. Hainsworth JD, Raefsky EL, Greco FA. Paclitaxel administered by a 1-hour infusion: a phase I-II trial comparing two schedules. Cancer J Sci Am 1995;1:281-287.
12. Hainsworth JD, Gray JR, Stroup SL et al. Paclitaxel, carboplatin and extended-schedule etoposide in the treatment of small-cell lung cancer; comparison of sequential phase II trials using different dose-intervals. J Clin Oncol 1997;15:3464-3470.
13. Hainsworth JD, Erland JB, Kalman LA et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997;15:2385-2393.
14. Bristol-Myers Squibb MJ. Paclitaxel (Taxol) package insert, Princeton, NJ, 1997.
15. Arbuck SG, Christian MC, Fisherman JS et al. Clinical development of Taxol. J Natl Cancer Inst Monogr 1993;11-24.
16. Onetto N, Canetta R, Winograd B et al. Overview of Taxol safety. J Natl Cancer Inst Monogr 1993;131-139.
17. Weiss RB, Donehower RC, Wiernik PH. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-1268.
18. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
19. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy 1997; 17:96S-104S.
20. Lopes NM, Adams EG, Pitts TW et al. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-242.
21. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-190.
22. Huizing MT, Keung ACF, Rosing H et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11:2127-2135.
23. Sonnichsen DS, Hurwitz CA, Pratt CB et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children. J Clin Oncol 1994;12:532-538.
24. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22 [suppl 6]:16-23.
25. Ohtsu T, Sasaki Y, Tamura T et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599-606.
26. Kearns CM. Personal communication, unpublished data.
27. Abu-Rustum NR, Aghajanian C, Barakat RR et al. Salvage weekly paclitaxel (Taxol) for recurrent ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:364a.
28. Langer C, Rosvold E, Millenson M et al. Paclitaxel by 1 or 24 hour infusion combined with carboplatin in advanced non-small cell lung carcinoma: a comparative analysis [abstract]. Proc Am Soc Clin Oncol 1997;16:452a.
29. Evans WK, Earle CC, Stewart DJ et al. Phase II study of one hour paclitaxel in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer 1997;18:83-94.
30. Hainsworth JD, Erland JB, Kalman LA et al. Phase I/II trial of paclitaxel (1-hour infusion) carboplatin, and gemcitabine in the treatment of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999; in press.
31. Greco FA, Stroup SL, Gray JR et al. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 1996;14:1642-1648.
32. Niell HB, Miller AA, Kumar P et al. Phase I/II trial of paclitaxel, cisplatin, and radiation therapy for stage III non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:447a.
33. Choy H, Akerley W, Safran H et al. Phase II trial of weekly paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:456a.
34. Gatzemeier U, Jagos U, Kaukel E et al. Phase II study of paclitaxel, carboplatin and oral etoposide in patients with small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:468a.
35. Mendiola C, del Campo JM, Massuti B et al. Phase II study of paclitaxel in 1-hour infusion with dose escalation and fixed cisplatin in untreated ovarian cancer: a trial of the Spanish Group for Ovarian Cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:359a.
36. Piccart MJ, Bertelsen K, Stuart G et al. Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience [abstract]. Proc Am Soc Clin Oncol 1997;16:352a.
37. Hainsworth JD, Jones SE, Mennel RG et al. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial. J Clin Oncol 1996;14:1611-1616.
38. Weiner LM, Colarusso P, Coia LR et al. Combined modality therapy for esophageal cancer: phase I trial of escalating doses of Taxol in combination with cisplatin, fluorouracil and 60 Gy radiation prior to esophagectomy [abstract]. Proc Am Soc Clin Oncol. 1997;16:309a.
39. Hainsworth JD, Peacock NW, Thomas M et al. Paclitaxel, carboplatin and prolonged infusion 5-FU in the treatment of advanced squamous cancer: a phase II trial [abstract]. Proc Am Soc Oncol 1997;16:401a.
40. Meluch AA, Hainsworth JD, Gray JR et al. Preoperative therapy with paclitaxel, carboplatin, 5-FU and radiation in the treatment of local esophageal cancer. Proc Am Soc Clin Oncol 1999; in press.
41. Rowinsky EK, Chaudry V, Cornblath DR et al. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;15:107-115.
42. Webster LK, Crinis NA, Morton CG et al. Plasma alcohol concentrations in patients following paclitaxel infusion. Cancer Chemother Pharmacol 1996;37:499-501.
43. Holmes FA, Valero V, Walters R et al. Phase III trial of paclitaxel administered over 3 or 96 hours for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:106a.
44. Holmes FA, Valero V, Buzdar AU et al. Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer. The long and short of it [abstract]. Proc Am Soc Clin Oncol 1998;16:110a.